Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Author: Muller, C.E.
Source: Current Medicinal Chemistry, Volume 7, Number 12, December 2000 , pp. 1269-1288(20)
Publisher: Bentham Science Publishers
Abstract:Developments in the field of adenosine receptor (AR) agonists of the past years are presented and discussed. Four different AR subtypes, A1, A2A, A2B, and A3, have been cloned from different species including the human receptors. Recombinant ARs expressed in permanent mammalian cell lines have found wide application in the screening of new ligands. Considerable differences are observed among data from different laboratories, using recombinant receptors for the assays. Reevaluation of compounds at all four receptor subtypes has shown that agonists that were believed to be selective for either A1 or A2A ARs may be potent A3 agonists and thus, non-selective. Potent and selective agonists for two of the AR subtypes, A1 and A3, have been developed. Truly selective A2A AR agonists, however, are presently not available. Potent or selective A2B agonists are still lacking. Since the treatment with AR agonists may lead to fast desensitization of the receptors, partial agonists, and indirect AR agonists, such as adenosine kinase inhibitors, or allosteric enhancers of adenosine binding, are being developed as site- and event-specific agents.
Keywords: A2a Selectivity; Acadesine; Adenosine Inhibitors; Adenosine Receptor Ligands; Agonists; Allosteric Enhancers; Antiinflammatory drugs; Fluorescence Labeled; Molecular Modelling Studies; N6 Substitution; Ribose Modification
Document Type: Review Article
Publication date: 2000-12-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.